Lethargy

New US product, ORMALVI™ (dichlorphenamide) tablets, launches for Primary Periodic Paralysis (PPP) treatment

Retrieved on: 
Mercredi, mai 8, 2024
FDA, General Health, Pharmaceutical, Health, Fetus, Cardiomyopathy, Torrent, Acidosis, Respiratory acidosis, Full, Diclofenamide, Risk, Pregnancy, Cognitive disorder, Milk, Aspirin, Metabolic acidosis, Dysgeusia, Hyperkalemia, Aplastic anemia, Partnership, PPP, Agranulocytosis, Anorexia nervosa, Human, Carbonic anhydrase inhibitor, SVP, Tablet, Incidence, Patient, Nursing, Lethargy, Serum, Hyperkalemic periodic paralysis, Diagnosis, Myopathy, Hypokalemic periodic paralysis, Paralysis, Paresthesia, Cycle, Stevens–Johnson syndrome, Hypokalemia, Quality of life, Argyreia nervosa, Sulfonamide, Coma, Pharmaceutical industry

We want to provide them with the support that they require to effectively manage their PPP.

Key Points: 
  • We want to provide them with the support that they require to effectively manage their PPP.
  • ORMALVI™ is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
  • Simply Stated: Research Updates in Periodic Paralysis - Quest | Muscular Dystrophy Association [online] Available at: https://mdaquest.org/simply-stated-research-updates-in-periodic-paralysis Accessed 23 Nov. 2023.
  • The impact of permanent muscle weakness on quality of life in periodic paralysis: a survey of 66 patients.

Boehringer Ingelheim and Atlanta Braves Foundation Partner to Support Shelter Dogs in Need

Retrieved on: 
Vendredi, avril 26, 2024
Dog, Atlanta Braves, Moxidectin, Shelter, Boehringer Ingelheim, Pet, Ozzie Albies, Animal, Breeding, Love, Partnership, DSM-IV codes, Seizure, Dog days, Human, Philadelphia Phillies, Tablet, Family, Vomiting, Truist Park, Diarrhea, Lethargy, Atlanta, Season, Associate

DULUTH, Ga., April 26, 2024 /PRNewswire/ -- Boehringer Ingelheim, the largest animal health company in Georgia and its NexGard® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) product, and the Atlanta Braves Foundation, the non-profit arm of the Atlanta Braves, are proud to announce a collaborative effort to support shelter adoptions across Braves Country.

Key Points: 
  • DULUTH, Ga., April 26, 2024 /PRNewswire/ -- Boehringer Ingelheim, the largest animal health company in Georgia and its NexGard® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) product, and the Atlanta Braves Foundation, the non-profit arm of the Atlanta Braves, are proud to announce a collaborative effort to support shelter adoptions across Braves Country.
  • On August 21, there will be a special on-field check presentation to the Ozzie Albies Foundation during the Braves home game against the Philadelphia Phillies to support shelter animals.
  • "We are incredibly excited to be part of this pet-centric initiative," said Daniel Watkins, Head of U.S. Pet at Boehringer Ingelheim.
  • In addition to providing much-needed resources, Boehringer Ingelheim is also working to raise awareness about the importance of adopting shelter animals.

Sepsis Alliance Applauds Reintroduction of Lulu's Law in Advance of Pediatric Sepsis Week

Retrieved on: 
Jeudi, avril 18, 2024
Congress, Patient, Personality, Stroke, System, Sepsis Alliance, United, Amputation, Sepsis, Convulsion, Hope, Hospital, Skin, Death, House, Legislation, Eye, Representative, Cost, Lethargy, Rash, Memory, Diagnosis, Pelvic floor dysfunction, Infection

WASHINGTON, April 18, 2024 /PRNewswire-PRWeb/ -- A bill named in memory of four-year-old Ana Lucía "Lulu" Haynes, who passed away from sepsis in 2014, has been reintroduced in the House of Representatives. It arrives ahead of next week's Pediatric Sepsis Week observance, which provides an annual opportunity to raise awareness of the symptoms of sepsis in children and honor the 75,000 children who, like Lulu, develop sepsis in the U.S. each year. The Sepsis Harm and Cost Reduction Act, or Lulu's Law, develops a U.S. strategy for responding to sepsis and launches a program of state-based information repositories to improve sepsis diagnosis, treatment, and outcomes. This will help to answer the many unanswered questions about this condition, improve our ability to diagnose and treat it, and organize the country's strategy for solving sepsis. The legislation is championed by Sepsis Alliance, the nation's first and leading sepsis organization, and jointly sponsored by Representative Mikie Sherrill (D-NJ-11), who represents Lulu's district, and Representative Larry Bucshon, M.D. (R-IN-08).

Key Points: 
  • The Sepsis Harm and Cost Reduction Act, or Lulu's Law, develops a U.S. strategy for responding to sepsis and launches a program of state-based information repositories to improve sepsis diagnosis, treatment, and outcomes.
  • According to Sepsis Alliance, children, particularly those under five, can be especially susceptible to developing sepsis.
  • "That's why, this Pediatric Sepsis Week, it is so heartening to see the reintroduction of Lulu's Law, a serious effort to tackle the enormous national burden of sepsis.
  • Sepsis Alliance applauds and sincerely thanks Representative Sherrill and Representative Bucshon for their leadership on this vital bill."

Mutual funds and safe government bonds: do returns matter?

Retrieved on: 
Jeudi, avril 25, 2024
ACT, Safe Haven, Research Papers in Economics, Flight, Policy, B.3, ICAPM, RT, Journal of International Economics, Krishnamurti, Business, CIP, International, Observation, P25, Safety, A23, Benchmarking, B.2, FX, Paper, TSD, Environment, Journal of Financial Economics, Bogdanov, Federal, Website, United, A14, Total, The Economic Journal, Eurozone, Face, G11, Quarterly Journal of Economics, Interest rate parity, History, WD, Investment, Liquidity premium, Politics, OLS, Statistics, G15, Caballero, PDF, Classification, ECB, Foreign exchange market, AC, P99, Federal funds, Froot, Lethargy, Social science, Interest, JEL, Bias, Journal, Research, Journal of Economic Literature, The Journal of Finance, E.3, Literature, Federal Reserve, Parity, European Central Bank, AA, Annual Review, Growth, Bank of England, FRED, S&P, Injection, Risk, Elasticity, Government, G12, Finance, BIS, S1, JL, E.1, Money, Depreciation, Asset, Treasury, Federal Reserve Economic Data, A11, A10, R2, Section 4, UMP, A4, Boj, Section 3, Accounting, SJ, Fed, Mutual fund, Lustig, University of Lausanne, Section 2, P75, Foreign-exchange reserves of India, Assets under management, A19, GBP, FE, American Economic Review, A22, E.5, A3, A21, Flight-to-liquidity, Aggregate demand, G23, WT, USD, Autocorrelation, CAD, UIP, Currency, XR, Quarterly Journal, Appendix H, Capital, P95, A6, Zhu, University, B.1, P50, CHF, Transmission, Swings, Estate (law), EUR, Bank for International Settlements, JPY, E.4, Central bank, Multicollinearity, Bank, Fixed effects model, Reproduction, CAP, The Atlanta Jewish Times, VIX, Data, Om, Lobster
Key Points: 

    Greater Good Charities and Boehringer Ingelheim Kick Off Fourth Year of Good Flights Program and Celebrate Successful Transport of More Than 12,800 Shelter Pets to Adoptive Homes Including Nearly 1,300 Asymptomatic Heartworm-Positive Dogs

    Retrieved on: 
    Lundi, avril 8, 2024
    DSM-IV codes, PLUS, Transport, Disease, Moxidectin, Seizure, Boehringer Ingelheim, Tablet, Diarrhea, Life, House, Dog, Lethargy, Euthanasia, Greater good, Coccidioides immitis, Safety, Terrebonne Parish, Louisiana, Good, Hookworm, Pet, Cat, Atmosphere of Earth, Itch, Animal rescue, Vomiting, Flea, Heart, Boehringer Ingelheim Animal Health, Pharmaceutical industry

    To kick off the fourth year of Good Flights, a special transport of more than 45 shelter pets will take place on April 8 from Louisiana to the East Coast.

    Key Points: 
    • To kick off the fourth year of Good Flights, a special transport of more than 45 shelter pets will take place on April 8 from Louisiana to the East Coast.
    • Air and ground transports for Good Flights occur approximately five times a month and many have Save a Heart pets on them.
    • “The Good Flights Program and Save a Heart initiative represents a remarkable collaboration between Greater Good Charities and Boehringer Ingelheim,” said Dr. Julie Ryan-Johnson, Senior Associate Director - Shelter Engagement Program, Boehringer Ingelheim.
    • Good Flights covers transport costs, provides mentorship, pharmaceuticals, and furnishes much needed supplies including pet crates, bowls, and leashes.

    Quectel unveils its HCM511S high performance MCU Bluetooth module to power Low Energy compact connected devices

    Retrieved on: 
    Mardi, avril 9, 2024
    Hardware, IOT (Internet of Things), Building Systems, Semiconductor, Security, Construction & Property, Consumer Electronics, Technology, Audio, Video, Apps, Applications, Wearables, Mobile Technology, Telecommunications, Software, Networks, Mobile, Wireless, Cortex, Blood pressure, Temperature, PC, USART, Sport, Internet of things, SPI, Bluetooth Special Interest Group, Embedded, Secure, ARM, Bluetooth mesh networking, LCC, Engineering, PWM, RAM, VEX, Thermometer, I2S, CSO, Multimedia, ADC, Lethargy, Bluetooth

    Embedded World – Quectel Wireless Solutions, a global IoT solutions provider, is pleased to announce the launch of the HCM511S high-performance MCU Bluetooth module for compact connected devices such as digital keys, portable devices and battery-operated motion sensors.

    Key Points: 
    • Embedded World – Quectel Wireless Solutions, a global IoT solutions provider, is pleased to announce the launch of the HCM511S high-performance MCU Bluetooth module for compact connected devices such as digital keys, portable devices and battery-operated motion sensors.
    • Utilizing Bluetooth Low Energy 5.4, the module accommodates an ARM Cortex-M33 processor and features built-in 32KB RAM and either 352KB or 512KB flash memory to deliver efficient performance.
    • View the full release here: https://www.businesswire.com/news/home/20240409992885/en/
      Quectel unveils its HCM511S high performance MCU Bluetooth module to power Low Energy compact connected devices (Graphic: Business Wire)
      The HCM511S module features excellent receiver sensitivity, a maximum transmit power of +6 dBm to achieve long distance transmission and has been designed to enable compact, low-power devices to connect cost effectively.
    • “We’re delighted to bring the compact, high-performance HCM511S Bluetooth Low Energy MCU module to the market,” says Norbert Muhrer, President and CSO, Quectel Wireless Solutions.

    Alif Semiconductor Announces World's First BLE and Matter Wireless Microcontroller to Feature Neural Co-Processor for AI/ML Workloads

    Retrieved on: 
    Mardi, avril 9, 2024
    Cortex, Arm, LPA, BLE, Machine learning, Logic, LC3, Algorithm, DSP, HPA, WLCSP, Acceleration, Memory, Business, ARM Cortex-M, MCU, AI accelerator, Bluetooth Low Energy, Spacecraft, Senior, TWS, Architecture, Radio, DAC, NPU, TCM, GOPS, Family, MVE, Artificial intelligence, EEMBC, Lethargy, Video game

    PLEASANTON, Calif., April 9, 2024 /PRNewswire/ -- Alif Semiconductor®, a leading global supplier of secure, connected, power efficient Artificial Intelligence and Machine Learning (AI/ML) microcontrollers (MCUs) and fusion processors, today announced the launch of the BallettoTM family, the world's first Bluetooth® Low Energy (BLE) wireless microcontroller to feature hardware optimization for AI/ML workloads.

    Key Points: 
    • The Balletto family offers particularly strong performance in audio and sensor functions thanks to its excellent DSP and AI/ML capabilities and large on-die memory.
    • Neural network processing performance is up to 15x better than a Cortex-M4 processor can achieve.
    • Balletto includes the state-of-the-art multi-layered security fabric first introduced in Alif Semiconductors' Ensemble family of MCUs and fusion processors.
    • "Alif Semiconductor's Balletto family is targeting BLE challenges faced by the wireless audio and smart home industry today with a platform adapted to high bit-rate audio and the Matter ecosystem," said Reza Kazerounian, President and Co-Founder of Alif Semiconductor.

    Alif Semiconductor Announces World's First BLE and Matter Wireless Microcontroller to Feature Neural Co-Processor for AI/ML Workloads

    Retrieved on: 
    Mardi, avril 9, 2024
    Cortex, Arm, LPA, BLE, Machine learning, Logic, LC3, Algorithm, DSP, HPA, WLCSP, Acceleration, Memory, Business, ARM Cortex-M, MCU, AI accelerator, Bluetooth Low Energy, Spacecraft, Senior, TWS, Architecture, Radio, DAC, NPU, TCM, GOPS, Family, MVE, Artificial intelligence, EEMBC, Lethargy, Video game

    PLEASANTON, Calif., April 9, 2024 /PRNewswire/ -- Alif Semiconductor®, a leading global supplier of secure, connected, power efficient Artificial Intelligence and Machine Learning (AI/ML) microcontrollers (MCUs) and fusion processors, today announced the launch of the BallettoTM family, the world's first Bluetooth® Low Energy (BLE) wireless microcontroller to feature hardware optimization for AI/ML workloads.

    Key Points: 
    • The Balletto family offers particularly strong performance in audio and sensor functions thanks to its excellent DSP and AI/ML capabilities and large on-die memory.
    • Neural network processing performance is up to 15x better than a Cortex-M4 processor can achieve.
    • Balletto includes the state-of-the-art multi-layered security fabric first introduced in Alif Semiconductors' Ensemble family of MCUs and fusion processors.
    • "Alif Semiconductor's Balletto family is targeting BLE challenges faced by the wireless audio and smart home industry today with a platform adapted to high bit-rate audio and the Matter ecosystem," said Reza Kazerounian, President and Co-Founder of Alif Semiconductor.

    Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

    Retrieved on: 
    Mardi, mars 26, 2024
    Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

    DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

    Key Points: 
    • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
    • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
    • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
    • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

    Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

    Retrieved on: 
    Mardi, mars 26, 2024
    Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

    DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

    Key Points: 
    • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
    • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
    • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
    • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.